Olivia T. Van Gerwen

Olivia T. Van Gerwen

Auto-generated profile, based on publicly available information

Olivia T. Van Gerwen

Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
OGOlivia T. Van Gerwen
Olivia T. Van Gerwen
CMChristina A. Muzny
Christina A. Muzny
JMJeanne M. Marrazzo
Jeanne M. Marrazzo

1 June 2020 in Transgender Health
Verified
Journal Article
Open access
OGOlivia T. Van Gerwen
Olivia T. Van Gerwen
AJAditi Jani
Aditi Jani
DLDustin M. Long
Dustin M. Long
EAErika L. Austin
Erika L. Austin
KMKaren Musgrove
Karen Musgrove
CMChristina A. Muzny
Christina A. Muzny
Purpose: Despite reportedly high rates of human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs) among transgender people, laboratory-proven prevalence of these infections in this population has not been systematically reviewed. We performed a systematic review and meta-analysis of the medical literature involving laboratory-proven HIV and STI diagnoses among transgender people. Methods: A systematic review of the English literature regarding laboratory-proven HIV and/or STI testing in transgender populations within the last 50 years was performed. Preliminary meta-analyses assessing the prevalence of HIV and STIs among both transgender men and transgender women were performed. Given the heterogeneity of included studies, these analyses were difficult to interpret and not included in our results. Results: Our literature review identified 25 studies, representing 11 countries. All of these studies included transgender women, with 9 (36%) including data on transgender men. HIV was the most commonly studied STI, with prevalence ranging from 0% to 49.6% in transgender women and 0% to 8.3% in transgender men. For syphilis, gonorrhea, and chlamydia, respectively, prevalence ranged from 1.4% to 50.4%, 2.1% to 19.1%, and 2.7% to 24.7% in transgender women and from 0% to 4.2%, 0% to 10.5%, and 1.2% to 11.1% in transgender men. Site-specific testing practices for gonorrhea and chlamydia were variable. No studies reported prevalence data on trichomoniasis. Conclusion: The literature describing STIs and transgender people primarily focuses on transgender women and HIV. Data involving HIV and STIs among transgender men are lacking. These findings highlight opportunities for the future study of epidemiology of HIV/STIs in transgender men and the relevance of STIs in transgender people.

27 June 2021 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
OGOlivia T. Van Gerwen
Olivia T. Van Gerwen
MCMegan Clare Craig-Kuhn
Megan Clare Craig-Kuhn
AJAustin T. Jones
Austin T. Jones
JSJulia A. Schroeder
Julia A. Schroeder
JDJill Deaver
Jill Deaver
CMChristina A. Muzny
Christina A. Muzny

20 September 2019 in F1000Research
Verified
Journal Article
Open access
PDF file
OGOlivia T. Van Gerwen
Olivia T. Van Gerwen
CMChristina A. Muzny
Christina A. Muzny
Trichomonas vaginalisis the most common, curable non-viral sexually transmitted infection (STI) worldwide. Despite this burden of disease, it is not currently a reportable disease in the United States. Recent advances in the epidemiology, diagnosis, and management ofT. vaginalisinfection are described in this article. This includes updated global and U.S. prevalence data in women and men as well as recent epidemiological data in HIV-infected individuals and pregnant women. Advances in molecular diagnostics are also reviewed, as are data from recent clinical trials regarding the treatment of trichomonas in women.

4 July 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
OGOlivia T Van Gerwen
Olivia T Van Gerwen
ACAndres F Camino
Andres F Camino
JSJyoti Sharma
Jyoti Sharma
PKPatricia J Kissinger
Patricia J Kissinger
CMChristina A Muzny
Christina A Muzny
Trichomonas vaginalis infections in men are traditionally considered to be benign and consequently have been overlooked. However, men with this common sexually transmitted infection can experience urethritis, prostatitis, reduced fertility, and amplified human immunodeficiency virus risk. In addition, men are often asymptomatic and can unknowingly spread the infection to their female sexual partners. With advances in T. vaginalis diagnostics, more men are being diagnosed, yet the optimal method of treatment in men remains unknown. The purpose of this review is to discuss the epidemiology, natural history, diagnosis, and treatment of T. vaginalis among men.

31 March 2023 in Infectious Disease Clinics of North America
Verified
Journal Article
Closed access
OGOlivia T. Van Gerwen
Olivia T. Van Gerwen
SOSkye A. Opsteen
Skye A. Opsteen
KGKeonte J. Graves
Keonte J. Graves
CMChristina A. Muzny
Christina A. Muzny